Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab with or without intravenous immunoglobulin in childhood-onset steroid-dependent nephrotic syndrome
2017-000826-36Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in steroid-dependent nephrotic syndrome (SDNS) and nephrosis comparing Rituximab monotherapy with Rituximab plus intravenous immunoglobulin (2 arms). Primary endpoint: First relapse within 24 months. Started Mar 2018; status: completed.
02
Drugs
rituximabpolyvalent human immunoglobulin
03
Conditions
steroid-dependent nephrotic syndrome (SDNS)nephrosis
Beyond the preview
Go deeper on 2017-000826-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000826-36.